On the Horizon- Final Results of VENICE First-Line Hormone-Refractory Metastatic Prostate Cancer Trial Expected in 2012
Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They [...]
My Response to the New York Times About the Cost of Cancer Treatments
My recent Letter to the Editor of the New York Times in response to the Op-Ed piece decrying the cost of cancer treatments: Your recent editorial about the high cost of cancer drugs missed a [...]
The House Approves the FY12 DoD Appropriations Bill – Yea
We dodged a bullet… for now! I’m pleased to report that the House just approved the FY12 DoD Appropriations Bill by a vote of 331-83. No amendments were offered to reduce or eliminate CDMRP (the [...]
The House Votes to Restore Funding for the Prostate Cancer DOD Program to 2011 Levels!
Yesterday there was an amendment passed on the House floor to restore the Prostate Cancer Research Program's 2012 funding to $80 million. The Department of Defense (DoD) Appropriations Bill (H.R. 2219) originally was slated to [...]
Some Great News For Our European Brothers In Their Fight Against Advanced Prostate Cancer
Things are looking up for our European readers. It must be frustrating for people outside of the United States to read this blog and learn about the many advances we now have in the US [...]
From A Recent Post I Made on the AdvancedProstateCancer Support Group
My personal belief is what does it matter since all of our goals really should be finding ways to live our lives to the fullest, gain all possible life extensions while also maintaining a decent [...]